Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028639 | 0.98 | TSHR (0.61) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL138941 | 0.86 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL20276156 | 0.86 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL3008879 | 0.86 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL1524206 | 0.86 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL864613 | 0.86 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL20276142 | 0.86 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL9190024 | 0.86 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL1523809 | 0.86 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL1317368 | 0.86 | TSHR (0.79) | TSHRALDH1A1TP53HIF1AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239922-A1 | PHOTOCURABLE COMPOSITION | TOKYO OHKA KOGYO CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20210024674-A1 | POLYMER COMPOUND, COMPOSITION, INSULATING LAYER, AND ORGANIC THIN FILM TRANSISTOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-01-28 | — | — | US | disclosed |
| CN-106039313-A | Chemosensory receptor ligand-based therapies | 埃尔舍利克斯治疗公司 | 2016-10-26 | — | — | CN | disclosed |
| US-8318824-B2 | Hydrophilic polyolefin sintered body | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120095121-A1 | HYDROPHILIC POLYOLEFIN SINTERED BODY | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2174975-A1 | HYDROPHILIC POLYOLEFIN SINTERED BODY | Asahi Kasei Chemicals Corporation (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-7012064-B2 | Systemically administering cyclic peptide compound, salt, ester or prodrug for reducing toxicity associated with the administration of cyclosporin A | ENANTA PHARMACEUTICALS, INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-6784156-B2 | ESPECIALLY FOR TREATING ASTHMA | ENANTA PHARMACEUTICALS, INC. | 2004-08-31 | — | — | US | disclosed |
| EP-1365791-A2 | CYCLOSPORINS FOR THE TREATMENT OF RESPIRATORY DISEASES | Enanta Pharmaceuticals, Inc. (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030186855-A1 | Systemically administering cyclic peptide compound, salt, ester or prodrug for reducing toxicity associated with the administration of cyclosporin A | ENANTA PHARMACEUTICALS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030109426-A1 | Semisynthetic cyclosporin analogs of formula (I): treatment of asthma and other diseases characterized by airflow obstruction, their use as drugs as respiratory system disorders | ENANTA PHARMACEUTICALS, INC. | 2003-06-12 | — | — | US | disclosed |
| US-20020142946-A1 | Cyclosporins for the treatment of respiratory diseases | ENANTA PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002069902-A2 | CYCLOSPORINS FOR THE TREATMENT OF RESPIRATORY DISEASES | ENANTA PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186855-A1 | Systemically administering cyclic peptide compound, salt, ester or prodrug for reducing toxicity associated with the administration of cyclosporin A | CCR1, CCR6, CHP1 | TSHR 1449/4885ALDH1A1 3250/4885TP53 2539/4885 |
| US-20030109426-A1 | Semisynthetic cyclosporin analogs of formula (I): treatment of asthma and other diseases characterized by airflow obstruction, their use as drugs as respiratory system disorders | CYP2S1, CYP2U1, CYC1 | TSHR 1762/4885ALDH1A1 2327/4885TP53 4341/4885 |
| US-20020142946-A1 | Cyclosporins for the treatment of respiratory diseases | CYC1, CYP2S1, CHP1 | TSHR 2392/4885ALDH1A1 2962/4885TP53 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.